Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Wockhardt
Large Cap•2,386 Employees•IPO 1994
Current Price
₹1363.20
19.4 (1.44%)Updated
Today's Range
1307.5
₹1363.20
1378.4
52 Week Range
52W Low₹1086.70
52W High₹1868.80
₹1363.20
Downside25.44%
Upside37.09%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹22,969.88 Cr
Market Cap
Total market value of companyP/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.39
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-1.38
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
1.19%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
3.75%
ROCE
Return on Capital Employed. >15% is goodNet Margin
-0.77%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
1.15%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-0.14%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
13.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.46
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹267.90
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
49.10%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Promoter holding remains significant at 49.1%, indicating insider commitment.
- •FII and DII holdings increased, reflecting growing institutional confidence.
Weaknesses
5 points- •Consistent negative profitability with ROE -1.21% and EPS -7.66.
- •Zero dividend yield (0.00%) offers no direct shareholder returns.
Opportunities
4 points- •Capitalize on overall growth and increasing demand in pharmaceuticals.
- •Strategic R&D investments can open new revenue streams and market segments.
Threats
5 points- •Significant competition from larger, more profitable peers challenges market share.
- •Adverse regulatory changes or non-compliance could lead to penalties.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Muayyad Khorakiwala | 27 Dec 2024 | 27 Dec 2024 | 1,800 | 1,800 | - | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1533.70 | +₹170.50 | +12.51% |
| R3 | ₹1462.80 | +₹99.60 | +7.31% |
| R2 | ₹1420.60 | +₹57.40 | +4.21% |
| R1 | ₹1391.90 | +₹28.70 | +2.11% |
| PIVOT | ₹1349.70 | -13.50 | -0.99% |
| CURRENT | ₹1363.20 | - | - |
| S1 | ₹1179.20 | -₹184.00 | -13.50% |
| S2 | ₹1250.10 | -₹113.10 | -8.30% |
| S3 | ₹1278.80 | -₹84.40 | -6.19% |
| S4 | ₹1321.00 | -₹42.20 | -3.10% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-38.3% vs avg
4.50L
(10 Apr 2026)Delivery %+0.1% vs avg
41.3%
(10 Apr 2026)Avg Volume (20D)20-day average
7.30L
(11 Mar - 10 Apr)Avg Delivery %Trend ↑
41.2%
(11 Mar - 10 Apr)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Ajanta Pharma Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Caplin Point Laboratories Ltd |
 Concord Biotech Ltd |
 Emcure Pharmaceuticals Ltd |
 ERIS Lifesciences Ltd |
 Gland Pharma Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Wockhardt Ltd
Wockhardt Limited is a multinational pharmaceutical and biotechnology company with a global presence, operating in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and other international markets. Their core business encompasses the manufacturing and trading of a wide range of pharmaceutical, medicinal, botanical, and chemical products.
A significant portion of Wockhardt's business focuses on the research and development of innovative products, particularly in the area of infectious diseases. They have several products in various stages of clinical trials, including WCK5222 (phase 3, for sepsis and pneumonia), WCK 4282 (phase 3, for ESBL infections), WCK 6777 (phase 1, for gram-negative infections), and WCK 4873 (phase 3, for community-acquired bacterial pneumonia). This commitment to research and development underscores their strategic focus on advanced therapeutics.
Beyond infectious disease treatments, Wockhardt also manufactures and commercializes a diverse portfolio of products including rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters, and novel products along with their associated delivery devices. This demonstrates a commitment to addressing a broad range of healthcare needs, extending beyond infectious diseases into metabolic disorders.
Wockhardt's product portfolio further includes established commercial products such as Biovac-B (hepatitis B vaccine), WEPOX (recombinant human erythropoietin), WOSULIN (recombinant human insulin), and GLARITUS (recombinant insulin glargine). These commercially available products contribute significantly to their revenue stream and establish a strong market presence.
In addition to its own product development and commercialization, Wockhardt offers contract manufacturing services and provides active pharmaceutical ingredients (APIs) to other companies. This diversification of revenue streams through contract manufacturing enhances the company's overall financial stability and resilience.
COMPANY FACTS - WOCKPHARMA
Registered Address
Wockhardt Towers, Bandra Kurla Complex, Bandra (East)
Mumbai
MAHARASHTRA
IN
Tel: 912226534444
Website:https://www.wockhardt.com/
Investor Relations:http://www.wockhardt.com/investor-connect/annual-reports.aspx
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,386
IPO Date: 25/02/1994
MANAGEMENT - WOCKPHARMA
Dr. Habil Fakhruddin Khorakiwala
Executive Chairman of the Board
Mr. Deepak Madnani
Chief Financial Officer
Ms. Rashmi Mamtura
Compliance Officer, Company Secretary
Dr. Murtaza Habil Khorakiwala
Managing Director, Executive Director
Dr. Huzaifa Habil Khorakiwala
Executive Director
Ms. Zahabiya Habil Khorakiwala
Non-Executive Non- Independent Director
Ms. Amelia Fernandes
Non-Executive Independent Director
Mr. Akhilesh Gupta
Non-Executive Independent Director
Mr. Vinesh Jairath
Non-Executive Independent Director
Amb. Ahmad Javed
Non-Executive Independent Director
Investor Questions Answered
Wockhardt Ltd (WOCKPHARMA) Stock FAQs
Get answers to the most common questions about Wockhardt Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Wockhardt Ltd (WOCKPHARMA) is ₹1,363.2. Today, the stock has gained by ₹19.40 (1.44%), trading in a range of ₹1,307.5 to ₹1,378.4. The stock opened at ₹1,326.1 with a trading volume of 7,04,563 shares.
Wockhardt Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹22,969.88 crores, P/E ratio of 0.00, ROE of 1.19%, and ROCE of 3.75%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Wockhardt Ltd (WOCKPHARMA) is ₹1,868.8, while the 52-week low is ₹1,086.7. Currently trading at ₹1,363.2, the stock is 35.4% away from its 52-week low and 27.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Wockhardt Ltd stock at ₹1,363.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 1.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Wockhardt Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,363.2, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Wockhardt Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: 1.19%, ROCE: 3.75%, Dividend Yield: 0.00%, EPS: ₹-1.38, Book Value: ₹267.9, Debt-to-Equity: 0.46, and Current Ratio: N/A. The company's market cap stands at ₹22,969.88 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Wockhardt Ltd stock opened at ₹1,326.1 and is currently trading at ₹1,363.2, showing a gain of ₹19.40 (1.44%). The intraday high is ₹1,378.4 and low is ₹1,307.5. The trading volume stands at 7,04,563 shares, indicating moderate market participation today.
Wockhardt Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-1.38, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Wockhardt Ltd has a market capitalization of ₹22,969.88 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,363.2) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Wockhardt Ltd has a book value of ₹267.9 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,363.2, which is 408.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Wockhardt Ltd has a Return on Equity (ROE) of 1.19% and Return on Capital Employed (ROCE) of 3.75%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Wockhardt Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Wockhardt Ltd has a debt-to-equity ratio of 0.46, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Wockhardt Ltd has an Earnings Per Share (EPS) of ₹-1.38, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,363.2 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Wockhardt Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Wockhardt Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Wockhardt Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (1.19%), debt-to-equity (0.46), and growth rates. 2) Technical Analysis - Check 52-week range (₹1086.70 - ₹1868.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1363.20) with book value (₹267.90) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Wockhardt Ltd share is ₹5.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,363.2 is 27164x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Wockhardt Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1086.70 - ₹1868.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.46 indicates leverage. 4) Liquidity Risk - Based on trading volume of 7,04,563 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Wockhardt Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of 1.19%, market cap of ₹22,969.88 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.46), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Wockhardt Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,363.2, with a 52-week range of ₹1086.70 to ₹1868.80. Based on fundamentals like P/E (0.00), ROE (1.19%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Wockhardt Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1363.20. 2) Fundamental Deterioration - Declining ROE (currently 1.19%), increasing debt (D/E: 0.46), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Wockhardt Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu